Texas is currently home to 5071 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)
Recruiting
This is a comparative effectiveness study of two pragmatic models aiming to introduce palliative care for end stage liver disease patients. The 2 comparators are: Model 1: Consultative Palliative Care (i.e. direct access to Palliative Care provider), Model 2: Trained Hepatologist- led PC intervention (i.e. a hepatologist will receive formal training to deliver Palliative Care services) Primary Outcome: The change in quality of life from baseline to 3 months post enrollment as assessed by FACT-... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
04/05/2022
Locations: Baylor College of Medicine, Houston, Texas
Conditions: End Stage Liver Disease
Development of Protocols and Methods for Image Processing and Enhancement of Magnetic Resonance Imaging (MRI) Data.
Recruiting
The purpose of the study is to develop new methods for image processing and enhancement of MRI data. Different setting of acquisition parameters used in conventional clinical MRI protocols will be defined, to create "New Protocols". The specific aim of this study is to assess and to improve the performance of our image processing methods, by comparing diagnostic qualities of images obtained by conventional MRI protocols with those obtained by corresponding New Protocols' and processed by our im... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2022
Locations: Houston Medical Imaging, Houston, Texas
Conditions: MRI Image Enhancement
Umbilical Cord Blood Mononuclear Cells for Hypoxic Neurologic Injury in Infants With Congenital Diaphragmatic Hernia (CDH)
Recruiting
The purpose of this study is to investigate the use of autologous umbilical cord blood (UCB) mononuclear cells to mitigate hypoxic neurologic injury among infants with high-risk congenital diaphragmatic hernia (CDH).
Gender:
All
Ages:
Between 10 minutes and 7 days
Trial Updated:
03/31/2022
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Congenital Diaphragmatic Hernia
Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, dose-response trial in patients with chronic stable Heart Failure (HF) and reduced Left Ventricular Ejection Fraction (LVEF) to evaluate the efficacy and safety of three INL1 doses compared with placebo. Patients will be treated for approximately 12 weeks with one of three INL1 doses: 50 mg, 150 mg, 300 mg, or, placebo capsules, taken twice daily (BID).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/28/2022
Locations: East Texas Cardiology, Houston, Texas
Conditions: Heart Failure, Reduced Ejection Fraction
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial
Recruiting
The purpose of this research is to investigate the validity of a previous clinical trial named EH301, which showed beneficial effects of anti-oxidant therapies in patients with amyotrophic lateral sclerosis (ALS). If validated by this study, providing over-the-counter anti-oxidants would be a simple, low risk, low-cost approach to significantly slow or stop the progression of ALS, for which currently no effective treatment exists. It is currently thought that oxidative stress is a major cause of... Read More
Gender:
All
Ages:
Between 21 years and 80 years
Trial Updated:
03/25/2022
Locations: VA North Texas Health Care System, Dallas, Texas
Conditions: Amyotrophic Lateral Sclerosis (ALS)
Virtual Reality Pain Study
Recruiting
Investigating pain in hospitalized patients in two groups: virtual reality usage group vs standard of care
Gender:
All
Ages:
18 years and above
Trial Updated:
03/23/2022
Locations: Baylor Institute for Rehabilitation, Dallas, Texas
Conditions: Hospitalized Patients 18 Years of Age or Older With Pain
Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease
Recruiting
The major objective is to demonstrate the safety and efficacy of ANG-3070 in patients with primary glomerular disease and persistent proteinuria.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2022
Locations: Prolato Clinical Research Center, Houston, Texas
Conditions: Glomerular Disease, Proteinuria
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
Recruiting
This is a Phase 1 study of the combination of two drugs: MM-398 and Cyclophosphamide. The goal is to find the highest dose of MM-398 that can be given safely when it is used together with the chemotherapy drug Cyclophosphamide.
Gender:
All
Ages:
Between 12 months and 20 years
Trial Updated:
03/17/2022
Locations: UT Southwestern, Dallas, Texas
Conditions: Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma, Osteosarcoma
B2RAD Translational Medicine Study
Recruiting
Recent advances in understanding the molecular and cellular pathology of many diseases have resulted in direct benefit to today's patients. The translational research studies that have led to these advances relied on an integrated model of clinical and non-clinical laboratory investigations based on the analysis of human biospecimens that lead directly to drug discovery, drug validation, novel detection assays, and prognostic marker discovery. Translational research provides a unique mechanism t... Read More
Gender:
All
Ages:
All
Trial Updated:
03/14/2022
Locations: DHR Health Institute for Research and Development, Edinburg, Texas
Conditions: Specimens Are to be Collected From Subjects Who Are Having or Have Had a Fluid or Tissue Removed, a Biopsy or a Blood or Bone Marrow Draw
PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS
Recruiting
The recent rise in infections with the Omicron variant of the SARS-CoV-2 is alarming. Equally disconcerting is the fact that individuals who were previously vaccinated (< 6 months) and have co-morbidities that are considered high risk, are getting re-infected...a process referred to as "breakthrough". There is some evidence that in these high risk individuals, the gradual decrease in immunity against the virus as depicted by a drop in anti-SARS-CoV-2 antibodies, is responsible (partially or whol... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2022
Locations: Brownsville Independent School District, Brownsville, Texas
Conditions: SARS CoV 2 Infection, COVID-19
Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting
Recruiting
No therapeutic agent is currently approved for the treatment of SARSCoV-2 infection. More importantly, no intervention is currently available to mitigate the progression of disease from mid/moderate to serve particularly in high risk patients. Recognizing this limitation and urgency of finding a treatment for COVID-19, the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergencyuse of the unapproved product bamlanivimab or casirivimab + imde... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
03/14/2022
Locations: DHR Health Institute for Research and Development, Edinburg, Texas
Conditions: Covid19
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
Recruiting
This is a Phase 1, first-in-human, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312. It is anticipated that approximately 24 subjects will be enrolled in the dose-escalation phase of the study. JAB-3312 will be administered orally once daily (QD) in 21-day treatment cycles.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2022
Locations: The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Other Solid Tumors